DiaMonTech AG, a young innovative medical technology company, has been selected as a finalist for the 2023 SXSW Innovation Award in the Patient Safety Technology category. This prestigious award, presented as part of the South by Southwest (SXSW) festival, recognizes groundbreaking innovations in healthcare and technology.

During the festival, CEO and Co-Founder Thorsten Lubinski and CTO Dr. Michael Kaluza were able to have many conversations and present themselves to industry experts. This nomination highlights DiaMonTech as a leader in patient safety technology and emphasizes the company's commitment to addressing global health issues through cutting-edge technology.

Company Profile DiaMonTech

The German MedTech company DiaMonTech has developed a novel way to measure biomarkers reagent-free. The first product is a non-invasive blood-sugar monitor that achieves a comparable accuracy as invasive devices. Samsung and other international investors are excited about the technology and invested more than USD 17M  in the company.

Changing the reality of diabetes.

Founded in Berlin in 2015, DiaMonTech develops, produces and markets innovative solutions to measure biomarkers non-invasively. The pioneered and patented photothermal detection method has been researched at a German University over the last 15 years by one of the founders, Prof. Dr.Werner Mäntele. Convinced that this technology has the potential to revolutionize the point of care market, he founded DiaMonTech together with the experienced entrepreneur Thorsten Lubinski. The first product is a blood sugar monitor called D-Pocket that doesn’t require blood sampling, is easy to use and highly precise.

‍

For media inquiries, please contact:

Catalina Plesmann
hello@diamontech.de

‍